Huang C - Search Results

1

Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.

Xia X, Liu Y, Liao Y, Guo Z, Huang C, Zhang F, Jiang L, Wang X, Liu J, Huang H. Xia X, et al. Among authors: huang c, huang h. Eur J Pharmacol. 2019 Aug 5;856:172409. doi: 10.1016/j.ejphar.2019.172409. Epub 2019 May 25. Eur J Pharmacol. 2019. PMID: 31132355

2

Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer.

Xia X, Liao Y, Guo Z, Li Y, Jiang L, Zhang F, Huang C, Liu Y, Wang X, Liu N, Liu J, Huang H. Xia X, et al. Among authors: huang c, huang h. Oncogenesis. 2018 Sep 24;7(9):75. doi: 10.1038/s41389-018-0086-y. Oncogenesis. 2018. PMID: 30250021 Free PMC article.

3

Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling.

Liu N, Guo Z, Xia X, Liao Y, Zhang F, Huang C, Liu Y, Deng X, Jiang L, Wang X, Liu J, Huang H. Liu N, et al. Among authors: huang c, huang h. Eur J Pharmacol. 2019 Mar 5;846:1-11. doi: 10.1016/j.ejphar.2019.01.004. Epub 2019 Jan 9. Eur J Pharmacol. 2019. PMID: 30639309

4

Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.

Liao Y, Guo Z, Xia X, Liu Y, Huang C, Jiang L, Wang X, Liu J, Huang H. Liao Y, et al. Among authors: huang c, huang h. J Exp Clin Cancer Res. 2019 Apr 11;38(1):157. doi: 10.1186/s13046-019-1165-4. J Exp Clin Cancer Res. 2019. PMID: 30975171 Free PMC article.

5

Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.

Xia X, Huang C, Liao Y, Liu Y, He J, Guo Z, Jiang L, Wang X, Liu J, Huang H. Xia X, et al. Among authors: huang c, huang h. J Exp Clin Cancer Res. 2019 May 24;38(1):220. doi: 10.1186/s13046-019-1227-7. J Exp Clin Cancer Res. 2019. PMID: 31126320 Free PMC article.

6

Deubiquitination and stabilization of estrogen receptor α by ubiquitin-specific protease 7 promotes breast tumorigenesis.

Xia X, Liao Y, Huang C, Liu Y, He J, Shao Z, Jiang L, Dou QP, Liu J, Huang H. Xia X, et al. Among authors: huang c, huang h. Cancer Lett. 2019 Nov 28;465:118-128. doi: 10.1016/j.canlet.2019.09.003. Epub 2019 Sep 10. Cancer Lett. 2019. PMID: 31518603

7

Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.

Liao Y, Liu Y, Xia X, Shao Z, Huang C, He J, Jiang L, Tang D, Liu J, Huang H. Liao Y, et al. Among authors: huang c, huang h. Theranostics. 2020 Feb 10;10(8):3366-3381. doi: 10.7150/thno.41849. eCollection 2020. Theranostics. 2020. PMID: 32206096 Free PMC article.

8

Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.

Liu Y, Shao Z, Liao Y, Xia X, Huang C, He J, Hu T, Yu C, Jiang L, Liu J, Huang H. Liu Y, et al. Among authors: huang c, huang h. Eur J Pharmacol. 2020 Sep 15;883:173366. doi: 10.1016/j.ejphar.2020.173366. Epub 2020 Jul 15. Eur J Pharmacol. 2020. PMID: 32679184

9

ERα is a target for butein-induced growth suppression in breast cancer.

Huang C, Xia X, He J, Liu Y, Shao Z, Hu T, Yu C, Liu X, Xu Q, Liu B, Liu N, Liao Y, Huang H. Huang C, et al. Among authors: huang h. Am J Cancer Res. 2020 Nov 1;10(11):3721-3736. eCollection 2020. Am J Cancer Res. 2020. PMID: 33294263 Free PMC article.

10

The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression.

Xia X, Huang C, Liao Y, Liu Y, He J, Shao Z, Hu T, Yu C, Jiang L, Liu J, Huang H. Xia X, et al. Among authors: huang c, huang h. Cell Death Dis. 2021 Mar 26;12(4):329. doi: 10.1038/s41419-021-03607-w. Cell Death Dis. 2021. PMID: 33771975 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45,017 results

Search Page

Filters